J
J. Bauer
Researcher at University of Lausanne
Publications - 12
Citations - 184
J. Bauer is an academic researcher from University of Lausanne. The author has contributed to research in topics: Regimen & Breast cancer. The author has an hindex of 6, co-authored 12 publications receiving 180 citations.
Papers
More filters
Journal ArticleDOI
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study
Y. Seium,Roger Stupp,Thomas Ruhstaller,Pascal Gervaz,Gilles Mentha,M. Philippe,Abdelkarim S. Allal,C. Trembleau,J. Bauer,R. Morant,Arnaud Roth +10 more
TL;DR: OCFL is an overall well tolerated regimen with very high efficacy, which makes it most suitable for tumour control before surgery of metastatic disease.
Journal ArticleDOI
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Khalil Zaman,Robert Driscoll,Robert Driscoll,Diane Hahn,Patricia Werffeli,Patricia Werffeli,Simon L. Goodman,J. Bauer,Serge Leyvraz,Ferdy J. Lejeune,Roger Stupp,Curzio Rüegg,Curzio Rüegg +12 more
TL;DR: Only VEGF‐A and MMP‐9 consistently correlated to each other, elevated CRP levels were associated with tumor burden, whereas sVEGF‐R1 increased after tumor removal in colorectal cancer.
Journal ArticleDOI
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Verena Voelter,Abderrahim Zouhair,H. Vuilleumier,Maurice Matter,Hanifa Bouzourene,Serge Leyvraz,J. Bauer,Philippe Coucke,Roger Stupp +8 more
TL;DR: Neoadjuvant CPT-11 and HART allow for excellent local control; however, distant relapse remains a concern in this patient population.
Journal ArticleDOI
Elevated CA125 levels in patients with metastatic breast carcinoma.
L Perey,Daniel F. Hayes,Carlo Tondini,G. van Melle,J. Bauer,T Lemarchand,Marc A. Reymond,JP Mach,Serge Leyvraz +8 more
TL;DR: The performance characteristics of CA125 in breast cancer are not as satisfactory as for CA15-3, which should be considered the marker of choice in patients with disseminated breast carcinoma.
Journal ArticleDOI
Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor
Serge Leyvraz,Nicolas Ketterer,L Perey,J. Bauer,P. Vuichard,JPh Grob,Ph. Schneider,V. von Fliedner,Ferdy J. Lejeune,Fedor Bachmann +9 more
TL;DR: In the majority of patients, neurotoxicity and ototoxicity became dose limiting after three cycles of therapy, however, the average dose intensity delivered was about three times higher than in a standard regimen.